Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Aktis Oncology (NASDAQ:AKTS) Shares Slip: What's Pressuring the Stock and What Comes Next?

Aktis Oncology, Inc (NASDAQ:AKTS) has slipped in a September 2026 session, nudging the targeted-radiopharmaceutical developer back into focus during a busy stretch for freshly listed oncology names. Shares closed down 2.67% at $23.30 at last closing, a pullback that is modest by biotech standards, …

Nitish Kishor | 14 September 2026

Alamar Biosciences (NASDAQ:ALMR) Holds Steady: Why Investors Are Reassessing the Stock

Few 2026 healthcare debutants have captured investor imagination like Alamar Biosciences, Inc. (NASDAQ:ALMR). The proteomics company priced its initial public offering in April 2026 and has since become a closely followed name in the liquid-biopsy and precision-medicine arena. Shares closed up 0.43% at $27.89 …

Nitish Kishor | 14 September 2026

Annovis Bio (NYSE: ANVS) Sets October 14 Special Meeting on Share Increases

Annovis Bio, Inc. (NYSE: ANVS) will ask shareholders on October 14, 2026, to approve a charter amendment raising authorized common stock from 70,000,000 shares to 140,000,000 shares. The same proposal would increase authorized preferred stock from 2,000,000 shares to 10,000,000 shares. The special meeting …

Vinay Lochav | 14 September 2026

Artiva Biotherapeutics Awards President 45,000 Shares at $0 (NASDAQ: ARTV)

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) awarded President and Head of R&D Miralles Gines Diego 45,000 shares at $0 per share on Sep. 9, 2026. The transaction was recorded under code A, an award or grant classification.

Vinay Lochav | 14 September 2026

Artiva Biotherapeutics Awards 30,000 Shares at $0 (NASDAQ: ARTV)

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) awarded Chief Medical Officer Banerjee Subhashis 30,000 shares at $0 per share on September 9, 2026. The same date also brought an award of 85,000 derivative securities.

Vinay Lochav | 14 September 2026

AtaiBeckley (NASDAQ: ATAI) CMO Also Disposes of 1,960,517 Derivatives

AtaiBeckley Inc. (NASDAQ: ATAI) Chief Medical Officer Craig Kevin James disposed of 8,437 shares on 11 September 2026, leaving him with zero shares.

Vinay Lochav | 14 September 2026

AtaiBeckley Inc. (NASDAQ: ATAI) Rao Srinivas Disposes of 216,442 Shares

AtaiBeckley Inc. (NASDAQ: ATAI) shares totaling 216,442 were disposed of by Rao Srinivas across two transactions. His reported share holdings were zero after the transactions.

Vinay Lochav | 14 September 2026

Barinthus Biotherapeutics Insider Transfers 8,797,770 Shares

Barinthus Biotherapeutics plc. saw Oxford Science Enterprises plc transact 8,797,770 shares at $0.11 per share.

Vinay Lochav | 14 September 2026

Aardvark Therapeutics (NASDAQ: AARD) Sun Nelson Sells 76,754 Shares at $5.00-$5.18

Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares were sold by Sun Nelson in two transactions involving 76,754 shares. The reported sales leave Nelson with a stated post-transaction holding in the company’s shares.

Vinay Lochav | 14 September 2026

ACADIA PHARMACEUTICALS INC (NASDAQ: ACAD) Settlement Hearing Scheduled for 2027

ACADIA PHARMACEUTICALS INC (NASDAQ: ACAD) must notify stockholders about a proposed settlement in case 3:23-cv-02293 after a federal court granted preliminary approval on August 24, 2026. If approved, the resolution would affect holders’ rights to challenge the settlement and pursue released claims.

Vinay Lochav | 14 September 2026
Support

Hi! How can we help you today?

Loading…